Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial.

In the modified-ITT population, the efficacy of IVIG treatment on the rates of ongoing pregnancy at 22 weeks of gestation or live birth did not reach statistical significance, since a total of 13 pregnancies were excluded due to chromosome abnormality of miscarriages.

also in 111,027 other papers